Amarin (AMRN) Receives Additional Patent Allowance for Vascepa
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Amarin (AMRN) Vascepa Growth Continues; Sees Limited Negative Read-Through from Merck's HPS2-THRIVE
March 11, 2013 10:54 AM EDTMKM Partners commented on Amarin Corporation (NASDAQ: AMRN) Monday as Vascepa prescription continue to gain momentum although sales might fall below the consensus.
The firm notes that after eight weeks, Vascepa total weekly prescriptions increased to 1,017 for the week ending March 1 from 838 the week prior (up 21% week over week). Analyst Jon LeCroy said current growth continues, assuming a wholesale cost of $184 per prescription and a prescription under-reporting rate of 22%, that would... More
